CRYSTALLINE SOLID AND AMORPHOUS FORMS OF (-)- HALOFENATE

摘要

The present invention provides crystalline solid and amorphous forms of (-)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (-)-halofenate.